On September 22, 2022 Servier and Oncodesign Precision Medicine (OPM) reported a collaborative research agreement, named ‘STarT Pancreas’, to identify and validate new therapeutic targets in Pancreatic Ductal Adenocarcinoma (Press release, Servier, SEP 22, 2022, View Source [SID1234621358]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The three-year agreement between Oncodesign Precision Medicine (OPM) and Servier includes two steps: Co-construction of an AI analytical platform based on data generated in the OncoSNIPE clinical trial and identification of targets with this platform; then experimental validation of the pre-selected targets.

Dr. Walid S. Kamoun, Servier’s Director of R&D Oncology: "We are delighted to initiate this collaboration with OPM, and to contribute to the development of an AI-based data analysis solution that could enable us to identify new therapeutic targets in pancreatic ductal adenocarcinoma, a dreaded cancer increasing in industrialized countries. This partnership is in line with the Group’s strategy of making the fight against cancer one of its strategic priorities, targeting hard-to-treat cancers for which treatment options are limited."

Pancreatic cancer is considered as one of the most difficult cancers to treat, due to its insidious symptoms and high degree of malignancy leading to a high mortality rate.